Conexeu Sciences Inc., a preclinical-stage biotech company, will present at the Controversies & Conversations in Laser & Cosmetic Surgery Symposium on August 15, 2026, arguing that cosmetic and reconstructive medicine should shift from injectables and fillers to extracellular matrix–based tissue regeneration, with its lead device candidate Ten-Minute Tissue designed to solidify from liquid to gel in roughly ten minutes at body temperature.
Category: Vericel Corporation
Regenerative Medicine’s Next Chapter: Inside the Race to Make the Body Rebuild Itself
Conexeu Sciences Inc. (Nasdaq: CNXU), an early-stage regenerative medicine company that began trading on the Nasdaq in May 2026, is developing a proprietary collagen-based extracellular-matrix platform called CXU™ for tissue restoration across wound care, aesthetics, and reconstruction. The article surveys the broader regenerative medicine sector, which independent market researchers estimate at tens of billions of dollars in 2026 with forecasts pointing to over US$100 billion within a decade at compound annual growth rates in the high-teens to mid-20s percent range.
The Quiet Revolution in Regenerative Medicine: From Replacing Tissue to Rebuilding It
Conexeu Sciences Inc. (NASDAQ: CNXU), which began trading in late May 2026, reported on June 8, 2026 that it had transferred standardized formulation methods to a contract manufacturing organization and advanced manufacturing scale-up activities for its lead CXU™ wound-care device candidate, targeting a 510(k) premarket notification submission to the FDA in the first quarter of 2027.
The Newest Name on Nasdaq Wants to Help the Body Rebuild Itself
Conexeu Sciences Inc., a Reno-based biotech company, began trading on Nasdaq on May 21, 2026, under the ticker CNXU with a regenerative tissue platform called CXU™ designed to support the body’s own tissue regeneration across multiple indications including a 3D-bioprinted breast reconstruction scaffold called B.R.E.A.S.T.™, which remains investigational and not yet submitted to the FDA.